Delivery Order SPE2DB22D2214-SPE2DB24FS4DL
Award Date 3/28/24
Potential Completion Date 3/29/24
Potential Value $24K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $3,874.29 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the supply of JANUMET XR 50-1,000 mg tablets in 60-count packages. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of JANUMET XR 50-500 mg tablets. The $1,418.23 contract has a firm fixed price and an ultimate completion date of April 30, 2024. Amerisourcebergen Drug Corp is the prime contractor, and there is no set-aside designation for this award. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $2,183.84 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide JANUMET XR 50-1,000 MG tablets in quantities of 180 per bottle. This delivery order is part of a larger indefinite delivery contract with a potential value of $999,999,999.00 awarded to AmerisourceBergen Drug Corp as a single award, which serves as the primary vehicle for the company to deliver...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,564,072,292 units of the pharmaceutical product JANUMET XR 50-1,000 mg tablets in 180-count packages. The total ceiling value of the contract is $2,687.00 with a period of performance through March 26, 2024. The contract does not have a set-aside designation. AmerisourceBergen Drug Corp holds an Indefinite...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply JANUMET XR 100-1,000 MG tablets. The contract has a potential value of $2,450.76 and a completion date of February 27, 2024. Amerisourcebergen Drug Corp is the prime contractor and serves as a pharmaceutical and medical supply provider to the Department of Defense through multiple DLA contracts, including an indefinite...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $2,745.04 to AmerisourceBergen Drug Corp, a leading global pharmaceutical distributor, to provide JANUMET XR 50-1,000 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 awarded by DLA to AmerisourceBergen Drug Corp, which serves as the prime contractor to deliver a comprehensive range of pharmaceutical products and medical supplies to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $7,147.50 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4563981933 JANUMET XR 50-1,000 MG TABLET 180S. This delivery order contract has an ultimate completion date of March 18, 2024. AmerisourceBergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA with a potential value of $999,999,999.00 through December...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $42,641.11 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distributor. The contract is for the supply of Janumet XR 50-1,000 mg tablets in quantities of 180 per unit. The delivery order is part of a larger indefinite delivery contract (IDC) previously awarded to Amerisourcebergen Drug Corp by DLA, valued at up to $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,326.40, is for the delivery of JANUMET XR 50-1,000 MG tablets in quantities of 180 per bottle. The contract is a Delivery Order with a Firm Fixed Price pricing type and has a completion date of December 14, 2023. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division. The $6,462.38 firm-fixed-price contract is for the supply of 180 count bottles of the pharmaceutical product JANUMET XR 50-1,000 MG TABLET. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for a comprehensive range of medical...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB24FS4DLDelivery Order
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide JANUMET XR 50-1,000 MG tablets in 180-count bottles. The $23,816.02 award has a performance period through March 29, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver pharmaceuticals and medical supplies to support the Department of Defense. This award does not have a set-aside designation.
Generated 6/27/24, 10:59 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 3/28/24 |